1. [Edifice program: analysis of screening exam practices for cancer in France]
- Author
-
Blay, Jean-Yves, Eisinger, François, Rixe, Olivier, Calazel-Benque, Anne, Morère, Jean-François, Cals, Laurent, Coscas, Yvan, Dolbeault, Sylvie, Namer, Moïse, Serin, Daniel, Roussel, Claire, Pivot, Xavier, Oncogénèse et progression tumorale, Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Cancérologie (Inserm U599/IPC), Université de la Méditerranée - Aix-Marseille 2-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Capio Clinique du Parc, Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hopital Font-Pre, Clinique de la Porte de St Cloud, Unité de Psycho-Oncologie (UPO), Institut Curie [Paris], Centre Azuréen de cancérologie, Centre Azureen de cancérologie, Institut Sainte Catherine [Avignon], ROCHE SAS, Roche SAS, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Saas, Philippe, Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])
- Subjects
Adult ,Male ,Lung Neoplasms ,[SDV.IMM] Life Sciences [q-bio]/Immunology ,MESH: Mammography ,Breast Neoplasms ,Sex Factors ,MESH: Sex Factors ,Humans ,MESH: Family Practice ,Aged ,MESH: Age Factors ,MESH: Aged ,MESH: Colonic Neoplasms ,MESH: Middle Aged ,MESH: Humans ,Rectal Neoplasms ,Age Factors ,MESH: Rectal Neoplasms ,Prostatic Neoplasms ,MESH: Adult ,Middle Aged ,MESH: Male ,MESH: Lung Neoplasms ,MESH: France ,MESH: Prostatic Neoplasms ,Colonic Neoplasms ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Female ,France ,Family Practice ,MESH: Female ,MESH: Breast Neoplasms ,Mammography - Abstract
International audience; INTRODUCTION: The practices of screening and the parameters influencing these practices are not well known in France. The objectives of the Edifice study were to analyze a large cohort of patients and doctors in order to further characterize these parameters. PATIENTS AND METHODS: The study was performed by the Institute TNS Healthcare-SOFRES, and included 2 parallel studies: 1) on 1 609 healthy persons representative of the global French population and aged 40 to 75 years (N = 1 509), with an over representation of patients aged 50 to 74 years living in the 22 pilot French departments pilots; 2) on 600 generalist practitioners. Data were collected and analyzed by the expert panel... RESULTS: Ninety-three, 25, 36 and 6% of the patients in the general population declared to have performed at least one a screening exam for breast, colon, prostate, and lung carcinoma respectively. Seventy, 20, 60 and 4% of GP declare to propose systematically to a 40-75-year-old patient a screening test for breast, colon, prostate, or lung cancer. For breast cancer screening the adhesion of the GP is independent of the date of implementation of a general screening in their own regions, while for colorectal screening, 34 and 20% of the patients living in the pilot versus other departments were screened. Overall, prostate cancer screening is recommended by the GP panel for 77.1% of patients aged 50 to 75 years. CONCLUSIONS: This study shows a good adhesion of screening procedures for GP and patients, shows that screening is improved by general screening policy in colorectal cancer, but that prostate cancer screening practices exceed what is recommended according to evidence based medicine.
- Published
- 2008
- Full Text
- View/download PDF